BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Grunenthal GmbH to Present Its Tamper Resistant Formulation Technology INTAC® at the Meeting & Exposition of the Controlled Release Society


7/13/2012 10:27:11 AM

BEDMINSTER, N.J., July 12, 2012 /PRNewswire/ -- This year's 39th Annual Meeting and Exposition of the Controlled Release Society (CRS) will take place in Quebec City, Canada from July 15-18, 2012. Grunenthal's participation in the event will include a booth exhibition as well as hosting an interactive Releasing Technology Workshop.

The annual CRS conference offers opportunities to learn about the most recent advancement in drug delivery science, one of which is Grunenthal's tamper resistant technology, INTAC®. INTAC® helps safeguard the intended use of oral extended release products while providing patients the same effective drug delivery as conventional formulations. Specifically, for prescription opioids, the application of INTAC® technology is an efficient means to combat unintended and intended tamper-based drug misuse and abuse.

In the course of the Releasing Technology Workshop section, Grunenthal will offer an interactive, educational seminar that is scheduled for Sunday, July 15, 2012 from 11:30-12:30p.m. Grunenthal will provide insight into applications of its tamper resistant technology, development of the technology, manufacturing opportunities as well as description of its properties. At the INTAC® information booth (#128), Grunenthal experts will discuss and present more details of the innovative INTAC® technology. Booth visitors are invited to personally experience the outstanding crush resistant properties of INTAC® tablets in attempting to smash the tablets by hammer strokes.

About INTAC®
Tablets produced using INTAC® technology are designed to resist crushing even by heavy hammer blows, foiling the key step in most forms of opioid abuse. In addition to their high breaking strength tablets produced by the INTAC® process form a gel in solutions that cannot be readily injected or snorted, and they resist extraction of active drug by a wide range of solvents. The mechanical stability is created by the combination of specific excipients together with a unique manufacturing process. INTAC® is the leading tamper resistance technology now in use, with already two FDA-approved products available in the United States. INTAC® manufacturing is established at commercial scale in the US and Europe. The technology is available for licensing to interested companies for various opportunities. Companies licensing INTAC® technology for their products are following a proven approach with a track record of regulatory approval. For more information about INTAC® please visit http://www.intac.grunenthal.com.

About Grunenthal
The Grunenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation. Grunenthal is one of the last five research-oriented pharmaceutical corporations with headquarters in Germany which sustainably invests in research and development. These investments amounted to about 25 percent of revenues in 2011. Grunenthal's research and development strategy concentrates on select fields of therapy and state-of-the-art technologies. We focus on the intensive search for new ways to treat pain better, more effectively and with fewer side-effects than before. Altogether, the Grunenthal Group has affiliates in 26 countries worldwide. Grunenthal products are sold in more than 155 countries and today approximately 4,200 employees are working for the Grunenthal Group worldwide. In 2011, Grunenthal achieved revenues of euro 947 mn.

Contacts:


Grunenthal USA, Inc.

Grunenthal GmbH, Germany

Alexander Kraus, PhD

Kai Strothmann, PhD

Vice President

Phone: +49 241 569 1796

Program Management Global TRF Business


One Pluckemin Way

Frank Schoenrock

Bedminster, NJ 07921

Vice President Corporate Communications



Phone: +1 908-745-2271

Phone: +49 241 569 1568

alexander.kraus@grunenthal.com

frank.schoenrock@grunenthal.com

Grunenthal GmbH, 52099 Aachen, Germany, www.grunenthal.com


SOURCE Grünenthal Group



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES